Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors

Clinical and Experimental Allergy, Supplement

Volumn 26, Issue 2, 1996, Pages 2-9

  Banner, K H ^a   Page, C P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; THEOPHYLLINE;

ALLERGY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CONFERENCE PAPER; DRUG BLOOD LEVEL; EOSINOPHIL; HUMAN; LUNG LAVAGE; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; PHOSPHODIESTERASE INHIBITORS; THEOPHYLLINE;

EID: 0029927628     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (99)

1. Weinburger M, Hendeles L, Ahrens R. Pharmacological management of reversible obstructive airways disease. Med Clinics N Amer 1980; 65:579-613.
2. Persson CGA. Overview of effects of theophylline. J Allergy Clin Immunol 1986; 78:780-7.
3. Persson CGA, Pauwels RA. Pharmacology of anti-asthma xanthines. In: Handbook of Experimental Pharmacology, Page CP, Barnes PJ, eds, Springer-Verlag Berlin, Heidelberg, New York: 1991; 98:207-26.
4. Grewe SR, Chan SC, Safko MJ, Hanifin JM. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol 1982; 70:452-7.
5. Giembycz MA, Kelly JJ. Current status of cyclic nucleotide phosphodiesterase isozymes. In : Methylxanthines and phosphodiesterase inhibitors in the treatment of airways disease. Costello JF, Piper PS, eds. Parthenum Press 1994: 27-80.
6. Torphy TJ, Undem BJ. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 1991; 46:512-23.
7. Persson CGA. Xanthines as airway anti-inflammatory drugs. J Allergy Clin Immunol 1988; 81:615-7.
8. Pauwels R. The effects of theophylline on airway inflammation. Chest 1987; 92:32S-37S.
9. Ward AJM, McKenniff M, Evans JM, Page CP, Costello JF. Theophylline - an immunomodulatory role in asthma? Am Rev Respir Dis 1993; 147:518-23.
10. Pearce FL, Befus AD, Gauldie J, Bienenstock J. Effects of anti-allergic compounds on histamine secretion by isolated mast cells. J Immunol 1982; 128:2481-6.
11. Louis RE, Radermecker MF. Substance P induced histamine release from human basophils, skin and lung fragments: effect of nedocromil sodium and theophylline. Int Arch Allergy Appl Immunol 1990; 92:329-33.
12. Azzawi M, Johnston PW, Majamdar S, Kay AB, Jeffery PK. T-lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am Rev Respir Dis 1992; 145:1477-82.
13. Shore A, Dosch H, Gelfand E. Induction and separation of antigen dependent T helper and T suppressor cells in man. Nature 1978; 274:586-7.
14. Zocchi MR, Pardi R, Gromo G et al. Theophylline induced non-specific suppressor cell activity in human peripheral blood lymphocytes. J Immunopharmacol 1985; 7:217-34.
15. Schudt C, Tenor H, Wendel A et al. Effect of selective phosphodiesterase (PDE) inhibitors on activation of human macrophages and lymphocytes. Naunyn Schmiedeberg's Arch Pharmacol 1992; 345:R69 (Suppl.).
16. Scordamaglia A, Ciprandis G, Ruffoni S et al. Theophylline and the immune response: in vitro and in vivo effects. Clin Immunol Immunopathol 1988; 48:238-46.
17. Bruserud O. The effect of theophylline on T-lymphocyte activation in vitro. Clin Immunol Immunopathol 1984; 32: 111-8.
18. Limatibul S, Shore A, Dorsch HM, Gelfand E. Theophylline modulation of E-rosette formation: an indicator of T cell maturation. Clin Exp Immunol 1978; 33:503-13.
19. Toribio ML, Gutierrez-Ramos JC, Pezzi L, Marcos MAR, Martinez A. Interleukin-2-dependent autocrine proliferation in T cell development. Nature 1989; 342:82-5.
20. Hancock WW, Pleau ME, Kobzik L. Recombinant granulocyte-macrophage colony-stimulating factor down-regulates expression of IL-2 receptors on human mononuclear phagocytes by induction of prostaglandins. J Immunol 1988; 140:3021-5.
21. Mary D, Aussel C, Ferrua B, Fehlmann M. Regulation of interleukin 2 synthesis by cAMP in human T cells. J Immunol 1987 139:1179-84.
22. Robicsek SA, Blanchard DK, Djeu JY, Krzanowski JJ, Szentivanyi A, Polson JB. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol 1991; 42:869-77.
23. Thompson WJ, Ross CP, Pledger WJ, Strada SJ. Cyclic adenosine 3′:5′-monophosphate phosphodiesterase: distinct forms in human lymphocytes and monocytes. J Biol Chem 1976; 251:4922-9.
24. Banner KH, Bertin B, Moodley I, Page CP. Effect of selective PDE inhibitors on phytohaemagglutinin stimulated murine thymus cell proliferation. Br J Pharmacol 1995; 114:207P.
25. Marcoz AF, Prigent M, Lagarde M, Nemoz G. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. Mol Pharmacol 1993; 44:1027-35.
26. Giembycz MA, Corrigan C, Kay AB, Barnes PJ. Inhibition of CD4 and CD8 T-lymphocyte proliferation and cytokine secretion by selective phosphodiesterase inhibitors: correlation with cyclic AMP concentrations. Clin Exp Allergy 1994; 24:995A.
27. Essayan DM, Kagey-Sobotka A, Lichtenstein LM, Huang SR. Modulation of allergen-induced cytokine gene expression and proliferation by phosphodiesterase inhibitors in vitro. J Allergy Clin Immunol 1993; 91:254.
28. Hichami A, Boichot E, Vernhet L, Germain N, Legrand A, Lagente V. Effects of phosphodiesterase (PDE) inhibitors on the arachidonic acid release by human peripheral blood mononuclear cells. Eur Respir J 1994;7:741P.
29. Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharmacol 1993; 15:409-13.
30. Pazdur J, Krzystyniak K, Kopec M. Effects of dipyridamole on human blood lymphocytes. Biochem Pharmacol 1980; 29:2515-7.
31. Banner KH, Page CP. Effect of type III and IV isozyme selective PDE inhibitors on proliferation of human peripheral blood mononuclear cells. Br J Pharmacol 1994; 113:89P.
32. Chan SC, Hanifin JM. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J Lab Clin Med 1993; 121:44-51.
33. Cooper KD, Kang K, Chan SC, Hanifin JM. Phosphodiesterase inhibition by RO 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J Invest Dermatol 1985; 84:477-82.
34. Yokoyama A, Yamashita N, Mizushima Y. Inhibition of natural killer cell activity by oral administration of theophylline. Chest 1990; 98:924-7.
35. Coskey LA, Bitting J, Roth MD. Inhibition of natural killer cell activity by therapeutic levels of theophylline. Am J Respir Cell Mol Biol 1993; 9:659-65.
36. Calhoun J, Stevens CA, Lambert B. Modulation of superoxide production of alveolar macrophages and peripheral blood mononuclear cells by beta agonists and theophylline. J Lab Clin Med 1991; 117:514-22.
37. Dent G, Giembycz MA, Rabe KF, Wolf B, Barnes PJ, Magnussen H. Theophylline suppresses human alveolar, macrophage respiratory burst through phosphodiesterase inhibition. Am J Cell Mol Biol 1994; 10:565-72.
38. Lappin D, Riches DWH, Damerau B, Whaley K. Cyclic nucleotides and their relationship to complement-component-C2 synthesis in human monocytes. Biochem J 1984; 222:477-86.
39. 2) production in normal monocytes in vitro. Eur Resp J 1993; 175:3685.
40. Endres S, Fulle HI, Sinha B et al. Cyclic nucleotides differentially regulate the synthesis of tumor necrosis factor a and interleukin 1B by human mononuclear cells. Immunol 1991; 72:56-60.
41. Nicholson CD, Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes - their potential utility in the therapy of asthma. Pulmon Pharmacol 1993; 6:1-17.
42. Schade FU, Schudt C. The specific type III and IV PDE inhibitor, zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur J Pharmacol 1993;230:9-14.
43. Turner NC, Guermy T. The effects of phosphodiesterase inhibitors on macrophage superoxide generation. Thorax 1991; 46:P107.
44. Frigas E, Loegering BS, Gleich GJ. Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. Lab Invest 1980; 42:35-43.
45. Frigas E, Gleich G. The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol 1986; 77: 527-35.
46. Kita H, Abu-Ghazaleh RI, Gleich GJ, Abraham RT. Regulation of Ig-induced eosinophil degranulation by adenosine 3′, 5′ monophosphate. J Immunol 1991; 146: 2712-8.
47. Hatzelmann A, Tenor H, Schudt C. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil function. Br J Pharmacol (in press).
48. Barnes PJ, Chung KF, Page CP. Inflammatory mediators and asthma. Pharmacol Rev 1988; 40:49-84.
49. Yukawa T, Kroegel C, Dent G, Chanez P, Ukena D, Barnes PJ. Effect of theophylline and adenosine on eosinophil function. Am Rev Resp Dis 1989; 140:327-3.
50. Nielson CP, Crowley JJ, Cusak BJ, Vestal RE. Therapeutic concentrations of theophylline and enprofylline potentiate catecholamine effects and inhibit leukocyte activation. J Allergy Clin Immunol 1986; 78:660-7.
51. Nielson CP, Crawley JJ, Morgan ME, Vestal RE. Polymorphonuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic 3′, 5′ adenosine monophosphate. Am Rev Respir Dis 1988; 137:25-30.
52. Souness JE, Carter CM, Diocee BK, Hassall GA, Wood LJ, Turner NC. Characterization of guinea pig eosinophil phosphodiesterase activity. Biochem Pharmacol 1991; 42: 937-45.
53. Nielson CP, Vestal RE, Sturm RJ, Heaslip R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol 1990; 86:801-8.
54. Dent G, Giembycz MA, Rabe KF, Barnes PJ. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonized zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors. Br J Pharmacol 1991; 103:1339-46.
55. Dent G, Evans PM, Chung KF, Barnes PJ. Zardaverine inhibits respiratory burst activity in human eosinophils. Am Rev Respir Dis 1989; 141:A878.
56. Souness JE, Maslen C, Webber SE et al. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Br J Pharmacol 1995; 115:39-46.
57. Kaneko M, Suzuki K, Furui H, Takagi K, Satake T. Comparison of theophylline and enprofylline effects on human neutrophil superoxide production. Clin Exp Pharmacol Physiol 1990; 17:849-59.
58. Schrier DJ, Imre RM. The effects of adenosine antagonists on human neutrophil function. J Immunol 1986; 137:3284-9.
59. Johnston M, Sindi H, Hussain A, Banks SM, Page C, Costello J, Kilfeather SA. Inhibition of chemotactic peptide-induced neutrophil superoxide release by theophylline, rolipram and isoprenaline is reduced by protein kinase A antagonist H89. Br J Pharmacol 1995; 114:29P.
60. Rivkin I, Neutze JA. Influence of cyclic nucleotides of phosphodiesterase inhibitors on in vitro human blood neutrophil chemotaxis. Arch Int Pharmacodyn 1977; 228:196-204.
61. Suttorp N, Weber U, Welsch T, Schudt C. Role of phosphodiesterase in the regulation of endothelial permeability in vitro. J Clin Invest 1993; 91:1421-8.
62. Rabe KF, Tenor H, Spaethe SM et al. Effects of phosphodiesterase (PDE) inhibition of prostanoid secretion of human bronchial epithelial cells in vitro. Eur Respir J 1994; 7:18S 742P.
63. Manzini S, Perretti F, Abelli L, Evangelista S, Seeds EAM, Page CP. Isbufylline, a new xanthine derivative inhibits airway hyperresponsiveness and airways inflammation in guinea pigs. Eur J Pharmacol 1993; 249:251-7.
64. Ali S, Mustafa SJ, Metzger WJ. Modification of allergen-induced airway obstruction and bronchial hyper-responsiveness in the allergic rabbit by theophylline aerosol. Agents & Actions 1992; 37:165-73.
65. Gristwood RW, Llupia J, Fernandez AG, Berga P. Effect of theophylline compared with prednisolone on the late phase airway leukocyte infiltration in guinea pigs. Int Arch Appl Immunol 1991; 94:293-4.
66. Underwood DC, Osborn RR, Novak LN et al. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, Rolipram. J Pharm Exp Ther 1993; 266:306-13.
67. Schudt C, Winder S, Eltze M, Kilian U, Beume R. Zardaverine: a cyclic AMP specific PDE III/IV inhibitor. Agents & Actions 1991; (Suppl. 34):379-402.
68. Kings MA, Chapman I, Kristersson A, Sanjar S, Morley J. Human recombinant lymphokines and cytokines induce pulmonary eosinophilia in the guinea pig which is inhibited by ketotifen and AH 21-132. Int Arch Allergy Appl Immunol 1990;91:354-61.
69. Lagente V, Moodley I, Perrin S, Mottin G, Junien J-L. Effects of isozyme selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea pig lung. Eur J Pharmacol 1994; 255:253-6.
70. Raeburn D, Underwood SL, Lewis SA et al. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol 1994; 113:1423-31.
71. Turner CR, Andresen CJ, Smith WB, Watson JW. Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. Am J Respir Crit Care Med 1994; 149:1153-9.
72. Sanjar S, Aoki S, Boubeckeur K et al. Eosinophil accumulation in pulmonary airways of guinea pigs induced by exposure to an aerosol of platelet activating factor: effect of anti-asthma drugs. Br J Pharmacol 1990; 99:267-72.
73. Sanjar S, Aoki S, Kristersson A, Smith D, Morley J. Antigen challenge induces pulmonary airway eosinophil accumulation and airway hyperreactivity in sensitized guinea pigs: the effect of anti-asthma drugs. Br J Pharmacol 1990; 99:679-86.
74. Banner KH, Page CP. Acute versus chronic administration of PDE inhibitors on allergen-induced pulmonary cell influx in sensitized guinea pigs. Br J Pharmacol 1995;114:93-8.
75. Gozzard N, Herd CM, Blake SM, Page CP. The effect of rolipram on antigen-induced airway responses in the neonatally immunized rabbit. Br J Pharmacol 1995 (in press).
76. Teixeira MM, Rossi AG, Williams TJ, Hellewell PG. Effects of phosphodiesterase inhibitors on cutaneous inflammation in the guinea pig. Br J Pharmacol 1994; 112: 332-40.
77. Erjefalt I, Persson CGA. Inflammatory passage of plasma macromolecules into airway wall and lumen. Pulm Pharmacol 1989; 2:93-102.
78. Persson CGA, Erejefalt I, Andersson P. Leakage of macromolecules from guinea-pig tracheobronchial microcirculation. Effects of allergen, leukotrienes, tachykinins and anti-asthma drugs. Acta Physiol Scand 1986; 127:95-104.
79. Erejefalt I, Persson CGA. Pharmacological control of plasma exudation into tracheobronchial airways. Am Rev Respir Dis 1991; 143:1008-14.
80. Persson CGA, Ekman M, Erejefalt I. Vascular anti-permeability effects of B-receptor agonists and theophylline in the lung. Acta Pharmacol Tox 1979; 44:216-20.
81. Boschetto P, Roberts NM, Rogers DF, Barnes PJ. The effect of anti-asthma drugs on microvascular leak in guinea-pig airways. Am Rev Respir Dis 1989; 139:416-21.
82. Raeburn D, Karlsson J-A. Effects of isoenzyme selective phosphodiesterase inhibitors on microvascular leak in guinea pig airways in vivo. J Pharmacol Exp Ther 1993; 267:1147-52.
83. Raeburn D, Woodman VR, Buckley GP, Karlsson J-A. Effect of phosphodiesterase inhibitors and salbutamol on ovalbumin-induced plasma extravasation in the anaesthetized sensitized guinea pig. Respir Med 1992; 86:85-6.
84. Naclerio RM, Bartenfelder D, Proud D et al. Theophylline reduces histamine release during pollen-induced rhinitis J Allergy Clin Immunol 1986; 78:874-6.
85. Mapp C, Boschetto P, Vecchio LD, Crescioli S, De Marzo N. Protective effects of anti-asthma drugs on late asthmatic reactions and increased airways responsiveness induced by toluene di-isocyanate in sensitized subjects. Am Rev Respir Dis 1987; 136:1403-7.
86. Pauwels R, Van Renterghem D, Van Der Straeten M, Johannesson N, Persson CGA. The effect of theophylline and enprofylline on allergen-induced bronchoconstriction. J Allergy Clin Immunol 1985; 76:583-90.
87. Condino-Neto A, Vilela MM, Cambiucci EC et al. Theophylline therapy inhibits neutrophil and mononuclear cell chemotaxis from chronic asthmatic children. Br J Clin Pharmacol 1991; 32:557-61.
88. O'Neill SJ, Sitar DS, Klass DJ, Taraska VA, Kepron W, Mitenko PA. The pulmonary disposition of theophylline and its influence on human alveolar macrophage bactericidal function. Am Rev Respir Dis 1986; 134:1225-8.
89. Venge P, Dahl R, Karlstrom R, Pederson B, Petterson CGB. Eosinophil and neutrophil activity in asthma in a one year double-blind trial with theophylline and two doses of inhaled budesonide. J Allergy Clin Immunol 1992; 89:190.
90. Crescioli S, Spinnazzi A, Plebani M et al. Theophylline inhibits early and late asthmatic reactions induced by allergens in asthmatic subjects. Ann Allergy 1991; 66: 245-51.
91. Hendeles L, Hasman E, Huang D, Cooper R, Delafuente J, Blake K. Alteration of allergen-induced airway hyperreactivity and late response by theophylline. Eur Respir J 1991; 4:1057P.
92. Sullivan PJ, Bekir S, Jaffar Z, Page CP, Jeffery PK, Costello J. The effects of low dose theophylline on the bronchial wall infiltrate after antigen challenge. Lancet 1994; 343:1006-8.
93. Torvik JA, Borish LC, Beam WR, Kraft M, Wenzel SE, Martin DJ. Does theophylline alter inflammation in nocturnal asthma? Am J Rev Crit Care 1994; 149:A210.
94. Shohat B, Volovitz B, Varsano I. Induction of suppressor T cells in asthmatic children by theophylline treatment. Clinical Allergy 1993; 13:487-93.
95. LaHat N, Nir E, Horenstein L, Colin AA. Effect of theophylline on the proportion and function of T-suppressor cells in athmatic children. Allergy 1985; 40:453-7.
96. Fink G, Mittelman M, Shohat B, Spitzer SA. Theophylline-induced alterations in cellular immunity in asthmatic patients. Clinical Allergy 1987; 17:313-6.
97. Kidney JC, Dominguez M, Rose M, Aikman S, Chung KF, Barnes PJ. Immune modulation by theophylline: the effect of withdrawal of chronic treatment. Am Rev Respir Dis 1993; 147:A772.
98. Kidney JC, Dominguez M, Taylor P et al. Withdrawal of chronic theophylline treatment increases airway lymphocytes. Thorax 1994; 49:396P.
99. Jaffar Z, Sullivan P, Page C, Costello J. Modulation of T-lymphocyte activity in atopic asthmatics by low dose theophylline therapy. Eur Respir J 1994; 7:160S.